Revathy Carnagarin

Dr. Revathy Carnagarin

Dobney Hypertension Centre, Royal Perth Hospital Research Foundation, Royal Perth Hospital, University of Western Australia, Australia
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2020 in JACC: Basic To Translational Science
Verified
Journal Article
Open access
LHLakshini Yasaswi Herat
Lakshini Yasaswi Herat
AMAaron L. Magno
Aaron L. Magno
CRCaroline Rudnicka
Caroline Rudnicka
JHJana Hricova
Jana Hricova
RCRevathy Carnagarin
Revathy Carnagarin
VMVance B. Matthews
Vance B. Matthews
Recent clinical trial data suggest a cardiorenal protective effect of sodium glucose cotransporter 2 (SGLT2) inhibition. We demonstrate that chemical denervation in neurogenic hypertensive Schlager (BPH/2J) mice reduced blood pressure, improved glucose homeostasis, and reduced renal SGLT2 protein expression. Inhibition of SGLT2 prevented weight gain, reduced blood pressure, significantly reduced elevations of tyrosine hydroxylase and norepinephrine, and protects against endothelial dysfunction. These findings provide evidence for significant crosstalk between activation of the sympathetic nervous system and SGLT2 regulation and possible ancillary effects on endothelial function, which may contribute to the observed cardiorenal protective effects of SGLT2 inhibition.

1 September 2021 in The Lancet
Verified
Journal Article
Closed access
CCClara Chow
Clara Chow
EAEmily R Atkins
Emily R Atkins
GHGraham S Hillis
Graham S Hillis
MNMark R Nelson
Mark R Nelson
CRChristopher M Reid
Christopher M Reid
HKHarry Klimis
Harry Klimis

1 December 2015 in Molecular and Cellular Endocrinology
Verified
Journal Article
Closed access
RCRevathy Carnagarin
Revathy Carnagarin
Arun DharmarajanArun Dharmarajan
Arun Dharmarajan
Crispin DassCrispin Dass
Crispin Dass

1 April 2023 in Hypertension
Verified
Journal Article
Closed access
GSGianni Sesa-Ashton
Gianni Sesa-Ashton
JNJanis Nolde
Janis Nolde
IMIda Muente
Ida Muente
RCRevathy Carnagarin
Revathy Carnagarin
RLRebecca Lee
Rebecca Lee
MSMarkus P SCHLAICH
Markus P SCHLAICH
Background: Recent sham-controlled randomized clinical trials have confirmed the safety and efficacy of catheter-based renal denervation (RDN). Long-term safety and efficacy data beyond 3 years are scarce. Here, we report on outcomes after RDN in a cohort of patients with resistant hypertension with an average of ≈9-year follow-up (FU). Methods: We recruited patients with resistant hypertension who were previously enrolled in various RDN trials applying radiofrequency energy for blood pressure (BP) lowering. All participants had baseline assessments before RDN and repeat assessment at long-term FU including medical history, automated office and ambulatory BP measurement, and routine blood and urine tests. We analyzed changes between baseline and long-term FU. Results: A total of 66 participants (mean±SD, 70.0±10.3 years; 76.3% men) completed long-term FU investigations with a mean of 8.8±1.2 years post-procedure. Compared with baseline, ambulatory systolic BP was reduced by −12.1±21.6 (from 145.2 to 133.1) mm Hg ( P <0.0001) and diastolic BP by −8.8±12.8 (from 81.2 to 72.7) mm Hg ( P <0.0001). Mean heart rate remained unchanged. At long-term FU, participants were on one less antihypertensive medication compared with baseline ( P =0.0052). Renal function assessed by estimated glomerular filtration rate fell within the expected age-associated rate of decline from 71.1 to 61.2 mL/min per 1.73 m 2 . Time above target was reduced significantly from 75.0±25.9% at baseline to 47.3±30.3% at long-term FU ( P <0.0001). Conclusions: RDN results in a significant and robust reduction in both office and ambulatory systolic and diastolic BP at ≈9-year FU after catheter-based RDN on less medication and without evidence of adverse consequences on renal function.

23 January 2019 in Frontiers in Neuroscience
Verified
Journal Article
Open access
PDF file
RCRevathy Carnagarin
Revathy Carnagarin
MKMarcio G. Kiuchi
Marcio G. Kiuchi
JHJan K. Ho
Jan K. Ho
VMVance B. Matthews
Vance B. Matthews
MSMarkus P SCHLAICH
Markus P SCHLAICH
The autonomic nervous system (ANS) has a significant influence on the structural integrity and electrical conductivity of the atria. Aberrant activation of the sympathetic nervous system can induce heterogeneous changes with arrhythmogenic potential which can result in atrial tachycardia, atrial tachyarrhythmias and atrial fibrillation (AF). Methods to modulate autonomic activity primarily through reduction of sympathetic outflow reduce the incidence of spontaneous or induced atrial arrhythmias in animal models and humans, suggestive of the potential application of such strategies in the management of AF. In this review we focus on the relationship between the ANS, sympathetic overdrive and the pathophysiology of AF, and the potential of sympathetic neuromodulation in the management of AF. We conclude that sympathetic activity plays an important role in the initiation and maintenance of AF, and modulating ANS function is an important therapeutic approach to improve the management of AF in selected categories of patients. Potential therapeutic applications include pharmacological inhibition with central and peripheral sympatholytic agents and various device based approaches. While the role of the sympathetic nervous system has long been recognized, new developments in science and technology in this field promise exciting prospects for the future.

20 August 2018 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
RCRevathy Carnagarin
Revathy Carnagarin
VMVance Matthews
Vance Matthews
MZMaria T K Zaldivia
Maria T K Zaldivia
KPKarlheinz Peter
Karlheinz Peter
MSMarkus P SCHLAICH
Markus P SCHLAICH
Over the last few years, evidence has accumulated to suggest that hypertension is, at least in part, an immune‐mediated inflammatory disorder. Many links between immunity and hypertension have been established and provide a complex framework of mechanistic interactions contributing to the rise in BP. These include immune‐mediated inflammatory processes affecting regulatory brain nuclei and interactions with other mediators of cardiovascular regulation such as the sympathetic nervous system. Sympathoexcitation differentially regulates T‐cells based upon activation status of the immune cell as well as the resident organ. Exogenous and endogenous triggers activate signalling pathways in innate and adaptive immune cells resulting in pro‐inflammatory cytokine production and activation of T‐lymphocytes in the cardiovascular and renal regions, now considered major factors in the development of essential hypertension. The inflammatory cascade is sustained and exacerbated by the immune flowviathe brain–bone marrow–spleen–gastrointestinal axis and thereby further aggravating immune‐mediated pathways resulting in a vicious cycle of established hypertension and target organ damage. This review summarizes the evidence and recent advances in linking immune‐mediated inflammation, sympathetic activation and their bidirectional interactions with the development of hypertension.Linked Articles: This article is part of a themed section on Immune Targets in Hypertension. To view the other articles in this section visithttp://onlinelibrary.wiley.com/doi/10.1111/bph.v176.12/issuetoc